Major pharma company to make significant investment in the UK28 Nov 2017
MSD's announcement to establish UK Discovery Centre in London an 'endorsement' of the government's Industry Strategy.
MSD (Merck and Co.) is set to establish a state-of-the-art life sciences discovery research facility in London, focussed on early bioscience discovery and entrepreneurial innovation.
The new UK Discovery Centre is anticipated to create 150 new research roles with the aim of attracting the brightest and best research scientists to work in London. The new site will accommodate approximately 800 additional staff for the UK domestic market and other European clinical functions currently based in MSD in the UK’s Hoddesdon headquarters.
The company is currently evaluating several potential locations in the London region with a target date of 2020 for operational readiness. In the meantime, MSD plans to establish a small temporary research facility in the area and is actively recruiting for suitably qualified scientific talent.
The proposed investment is in line with MSD Research Laboratories’ continued pursuit of new innovative scientific discovery and collaboration and follows similar investments in new biomedical centres in the San Francisco Bay Area and Cambridge Massachusetts. MSD believes that locating a research facility in London will expand MSD’s opportunity to engage with leading researchers in the UK and Europe.
“Strong discovery capabilities and the pursuit of scientific excellence are foundational to MSD’s mission to save and improve lives around the world,” said Dr Roger M. Perlmutter, president, MSD Research Laboratories. “This new London location will enable us to build on our proud legacy of invention and be an important contributor to the vibrant and rapidly growing London life sciences community while providing access for more collaborations within the European life science ecosystem.”
“We believe London to be a unique bioscience centre of excellence and a key component of the established golden triangle for academic science of London-Oxford-Cambridge,” said Louise Houson, managing director, MSD in the UK and Ireland. “This investment presents a major opportunity for us to work in collaboration with the UK Government to build on the forward-thinking and ambitious Industrial Strategy White Paper published by the Government today.”
It is intended that the UK Discovery Centre will become the location for MSD’s UK HQ, making the central London site a unique location within the UK pharmaceutical sector.
This landmark investment comes as a huge vote of confidence in the UK government’s approach to industrial strategy. Announcing the investment, Business Secretary Greg Clark said: "Our life sciences sector is one of the UK’s fastest developing industries, with a turnover in excess of £64 billion, employing 233,000 across the UK."
He added: "MSD’s commitment, and the wider Sector Deal investment we have secured, proves the process outlined in the Industrial Strategy can give companies the confidence and direction they need to invest in the UK. It will ensure Britain continues to be at the forefront of innovation and represents a huge vote of confidence in our Industrial Strategy."
Moulds & Tooling: A European success story
19 Sep 2018
While not quite an endangered species, the past fifteen years have not been easy ones for many European mould makers. Many, but not all, and IGS GeboJagema is a case in point – a case that shows the difference automation and focus can make. By Karen La...Read more
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years
18 Sep 2018
China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.Read more
Exciting skincare to protect against blue light emitted by phones and devices
10 Sep 2018
Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.Read more
Bio processing and manufacturing league table ranks US top and China bottom
3 Sep 2018
US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.Read more
Innovation "hindered by regulators"
27 Aug 2018
CPhI Annual Report expert sees CDMOs as potentially a source of process innovation but warns both regulator and license holders need to move past regulatory diktats.Read more
The 6-month FMD countdown - are you ready?
21 Aug 2018
With only 6 months left in which to become EU FMD-compliant, how can companies make the best use of their now limited options?Read more
Protecting the links between the UK and the EMA
14 Aug 2018
Now less than a year away from when the UK officially leaves the EU, the main goal remains the same - maintaining access to new drugs for patient health.Read more
Building contingency plans for an ambiguous post-Brexit market
31 Jul 2018
One company's positive approach to Brexit preparations, despite the lack of definition.Read more
Post-Brexit medicines - stuck in the UK?
30 Jul 2018
The EMA needs to provide more action and guidance to help UK pharmaceutical manufacturers, says Thomas Beck, senior vice president, quality management, Recipharm.Read more
Pharmacovigilance post-Brexit - simpler than previously thought?
24 Jul 2018
To meet new PV regulations, the industry has to face a "multitude of unknowns and an ever-moving target".Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation